Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 1 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 3 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 6 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (8 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADC 33-8 at 10 mg/kg on Day 1. The end of the study was day 44.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper/lower flank region with 1x10 ⁷of H2228 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 2,000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 48).

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. The end of the study was day 49.

Each female NOD.Cg-Prkdcscid II2rgmIVst/Vst (NPG)mouse was inoculated subcutaneously in the right upper flank region with 1x10 ⁷of H1792 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 47000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 57).

0.5x10⁶of A375 tumor cells (a melanoma cancer cell line having an IL13Ra2 copy number of 3.5x10⁵measured as described in Example 11)mixed in 1:10 dilution of MATRIGELR (Corning Life Sciences)with serum free media was implanted subcutaneously at the hind right flank in female BALB/c Nude mice on Day-10.When the average tumor volume reached about 140 mm³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of PBS vehicle or the tested ADC 33-8 just on Day 1 with a dose of 3 mg/kg. Body weights and tumor volumes were measured twice per week until the end of the study. Days post-dosing 18, the TGI (vs isotype ADC) was calculated.

Female athymic nude-Foxnlnu mice were implanted (left flank)with patient tumor cells. H score: 225. Tumor cells from one NSCLC patient were tested. When sufficient stock animals reached 1000-1500 mm ³,tumors were harvested for re-implantation into pre-study animals.Pre-study animals were implanted unilaterally on the left flank with tumor fragments harvested from stock animals.When the average tumor volume reached 150-300 mm ³on Day 0,mice were randomized into respective treatment groups and received intravenous injections of vehicle or the tested ADC 33-8 (5mg/kg).Body weights and tumor volumes were measured twice per week until the end of the study.Any animal exhibiting>20%net weight loss for a period lasting 7 days or mice displaying>30% net weight loss when compared to Day O was considered moribund and euthanized. Beginning on Day 0,tumor dimensions were measured twice weekly by digital caliper,and data including individual and mean estimated tumor volumes (Mean TV± SEM)was recorded for each group;tumor volume was calculated using the formula (1): TV=width2xlengthx0.52.

CB.17 female SCID mice were inoculated subcutaneously in the right up flank region with Jeko-1 tumor cells (5×10 ⁶)in 0.1 mL of PBS with Matrigel (1:1)for tumor development.When the tumor volumes reached about 150~250 mm ³on Day 1,mice were randomized into respective treatment groups (8 mice per group).The mice then received intravenous injections of vehicle or the tested ADC-00 at 7.5mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.

CB.17 female SCID mice were implanted (flank)with 1.0x10 ⁷of MDA-MB-231 tumor cells in 50%MATRIGELR (Corning Life Sciences)matrix (1:1 cell to Matrigel) on Day -13.When the average tumor volume reached about 200 mm ³on Day 1,mice were randomized into respective treatment groups (10 mice per group).The mice then received intravenous injections of the tested ADC-00 at 7.5 mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.Body weight and tumor volume were measured twice per week.The study was ended on Day 45.

CB.17 female SCID mice were implanted (flank)with 1.0x10 ⁷of MDA-MB-231 tumor cells in 50%MATRIGELR (Corning Life Sciences)matrix (1:1 cell to Matrigel) on Day -13.When the average tumor volume reached about 200 mm ³on Day 1,mice were randomized into respective treatment groups (10 mice per group).The mice then received intravenous injections of the tested ADC-11 at 7.5 mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.Body weight and tumor volume were measured twice per week.The study was ended on Day 45.

CB.17 female SCID mice were inoculated subcutaneously in the right up flank region with Jeko-1 tumor cells (5×10 ⁶)in 0.1 mL of PBS with Matrigel (1:1)for tumor development.When the tumor volumes reached about 150~250 mm ³on Day 1,mice were randomized into respective treatment groups (8 mice per group).The mice then received intravenous injections of vehicle or the tested ADC-11 at 7.5mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.

CB.17 female SCID mice were inoculated subcutaneously in the right up flank region with Jeko-1 tumor cells (5×10 ⁶)in 0.1 mL of PBS with Matrigel (1:1)for tumor development.When the tumor volumes reached about 150~250 mm ³on Day 1,mice were randomized into respective treatment groups (8 mice per group).The mice then received intravenous injections of vehicle or the tested ADC-13 at 7.5mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.

CB.17 female SCID mice were implanted (flank)with 1.0x10 ⁷of MDA-MB-231 tumor cells in 50%MATRIGELR (Corning Life Sciences)matrix (1:1 cell to Matrigel) on Day -13.When the average tumor volume reached about 200 mm ³on Day 1,mice were randomized into respective treatment groups (10 mice per group).The mice then received intravenous injections of the tested ADC-13 at 7.5 mg/kg on Day 1 and Day 8.PBS vehicle was tested in parallel,serving as a control.Body weight and tumor volume were measured twice per week.The study was ended on Day 45.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper/lower flank region with 1x10 ⁷of H2228 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 2,000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 48).

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. The end of the study was day 49.

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper/lower flank region with 1x10 ⁷of H2228 tumor cells (an NSCLC cell line having an IL13Ra2 copy number of about 2,000)in 0.1 mL of PBS mixed with MATRIGELR (1:1)for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. Body weights and tumor volumes were measured twice per week until the end of the study (Day 48).

Each female BALB/c Nude mouse was inoculated subcutaneously in the right upper flank region with 0.5x10 ⁶of SK-MES-1 tumor cells (a non-small cell lung cancer (NSCLC)cell line having an IL13Ra2 copy number of about 4x104)in 0.1 mL of PBS for tumor development.When the mean tumor size reached about 80-150 mm ³,mice were randomized into respective treatment groups (10 mice per group)and received intravenous injections of PBS vehicle or a single dose of the tested ADCs at 10 mg/kg on Day 1. The end of the study was day 49.